Cargando…
The pan-JAK inhibitor LAS194046 reduces neutrophil activation from severe asthma and COPD patients in vitro
Non-T2 severe asthma and chronic obstructive pulmonary disease (COPD) are airway chronic inflammatory disorders with a poor response to corticosteroids. LAS194046, a novel pan-Janus kinase (JAK) inhibitor, shows inhibitory effects on T2 allergic lung inflammation in rats. In this work we analyze the...
Autores principales: | Milara, Javier, Ballester, Beatriz, de Diego, Alfredo, Calbet, Marta, Ramis, Isabel, Miralpeix, Montserrat, Cortijo, Julio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948298/ https://www.ncbi.nlm.nih.gov/pubmed/35332239 http://dx.doi.org/10.1038/s41598-022-09241-6 |
Ejemplares similares
-
In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients
por: Milara, Javier, et al.
Publicado: (2019) -
PI3K, p38 and JAK/STAT signalling in bronchial tissue from patients with asthma following allergen challenge
por: Southworth, Thomas, et al.
Publicado: (2018) -
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
por: Ballester, Beatriz, et al.
Publicado: (2019) -
Mucins as a New Frontier in Pulmonary Fibrosis
por: Ballester, Beatriz, et al.
Publicado: (2019) -
Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
por: Ballester, Beatriz, et al.
Publicado: (2020)